Market closed
Cartesian Therapeutics/$RNAC
Cartesian Therapeutics shares are trading lower after the company reported its Q1 2025 financial results and provided a business update.
5 hours ago·Lightyear AI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Cartesian Therapeutics
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. The company leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function.
Ticker
$RNAC
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
66
ISIN
US8162123025
RNAC Metrics
BasicAdvanced
$270M
-
-$1.72
-
-
Price and volume
Market cap
$270M
52-week high
$41.87
52-week low
$8.85
Average daily volume
107K
Financial strength
Current ratio
12.343
Quick ratio
12.148
Long term debt to equity
-47.556
Total debt to equity
-64.556
Management effectiveness
Return on assets (TTM)
-7.50%
Return on equity (TTM)
55.29%
Valuation
Price to revenue (TTM)
6.83
Price to book
-12.4
Price to tangible book (TTM)
-1.23
Price to free cash flow (TTM)
-5.773
Growth
Revenue change (TTM)
31.91%
Earnings per share change (TTM)
-96.91%
What the Analysts think about RNAC
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Cartesian Therapeutics stock.
RNAC Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
RNAC Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
RNAC News
AllArticlesVideos
Cartesian Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
GlobeNewsWire·2 days ago
Cartesian Therapeutics Announces New Employment Inducement Grants
GlobeNewsWire·1 week ago
Cartesian Therapeutics' Descartes-08 Observed to Provide Deep and Sustained Benefits Through Month 12 After a Single Course of Therapy in Phase 2b Myasthenia Gravis Trial
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Cartesian Therapeutics stock?
Cartesian Therapeutics (RNAC) has a market cap of $270M as of May 09, 2025.
What is the P/E ratio for Cartesian Therapeutics stock?
The price to earnings (P/E) ratio for Cartesian Therapeutics (RNAC) stock is 0 as of May 09, 2025.
Does Cartesian Therapeutics stock pay dividends?
No, Cartesian Therapeutics (RNAC) stock does not pay dividends to its shareholders as of May 09, 2025.
When is the next Cartesian Therapeutics dividend payment date?
Cartesian Therapeutics (RNAC) stock does not pay dividends to its shareholders.
What is the beta indicator for Cartesian Therapeutics?
Cartesian Therapeutics (RNAC) does not currently have a Beta indicator.